Biotech Values

[DewDiligence]

HIV factoid: Approximately half of US diagnosed but untreated HIV carriers—roughly 100,000 people—have CD4 cell counts in the 350-500 range; this is the range in which proposed treatment guidelines recommend starting drugs while existing treatment guidelines recommend waiting.

In other words, patients in the 350-500 CD4 range will generate a quantum jump in the number of US HIV patients who are treated with such drugs as Atripla and Truvada when the proposed guidelines are finally implemented.

(Source: GILD 1Q09 CC)